Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP6 | P55212 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | DTYMK | P23919 | 1/20 | 0.40 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.38 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6429065 | 0.98 | CASP6 (0.43) | CASP6TSHRTDP1LMNAL3MBTL1 | |
| Ammonia Solution, Strong SCHEMBL30580416 | 0.98 | CASP6 (0.43) | CASP6TSHRTDP1LMNAL3MBTL1 | |
| SCHEMBL6429062 | 0.84 | ALDH1A1 (0.42) | CASP6TSHRTDP1LMNAGPR35 | |
| SCHEMBL30580417 | 0.82 | CA1 (0.38) | CASP6TDP1GPR35KMT2ACA1 | |
| SCHEMBL3264461 | 0.82 | PARP1 (0.42) | TSHRLMNAL3MBTL1GPR35KMT2A | |
| SCHEMBL30580418 | 0.82 | CA1 (0.38) | CASP6TDP1L3MBTL1GPR35KMT2A | |
| SCHEMBL12559304 | 0.82 | MAPK1 (0.41) | TSHRTDP1LMNAL3MBTL1GPR35 | |
| Potassium Ion SCHEMBL30721056 | 0.82 | CA1 (0.38) | CASP6TDP1GPR35KMT2ACA1 | |
| SCHEMBL11017953 | 0.82 | CASP6 (0.36) | CASP6TSHRTDP1LMNAL3MBTL1 | |
| SCHEMBL2039324 | 0.78 | VCAM1 (0.43) | TSHRTDP1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005007625-A2 | HETEROCYCLIC AMIDES WITH ANTI-TUBERCULOSIS ACTIVITY | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2005-01-27 | — | — | WO | claimed |
| US-20250386828-A1 | PLANT GROWTH PROMOTER | NIPPON PAPER INDUSTRIES CO., LTD. (JP) | 2025-12-25 | — | — | US | disclosed |
| WO-2024024851-A1 | AGENT FOR SUPPRESSING DECREASE IN YIELD AMOUNT | デンカ株式会社 | 2024-02-01 | — | — | WO | disclosed |
| WO-2023176347-A1 | METHOD FOR CULTIVATING CITRUS PLANT, AND LIQUID COMPOSITION | デンカ株式会社 | 2023-09-21 | — | — | WO | disclosed |
| US-20110144321-A1 | SYNTHETIC INTERMEDIATES AND PROCESSES | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-06-16 | — | — | US | disclosed |
| US-20110144321-A1 | SYNTHETIC INTERMEDIATES AND PROCESSES | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-06-16 | — | — | US | disclosed |
| US-7833331-B2 | Non-toxic corrosion-protection pigments based on cobalt | UNIVERSITY OF DAYTON (US) | 2010-11-16 | — | — | US | disclosed |
| US-7789958-B2 | Non-toxic corrosion-protection pigments based on manganese | UNIVERSITY OF DAYTON (US) | 2010-09-07 | — | — | US | disclosed |
| WO-2010011748-A2 | SYNTHETIC INTERMEDIATES AND PROCESSES | BIOCRYST PHARMACEUTICALS, INC. (US) | 2010-01-28 | — | — | WO | disclosed |
| US-20090163628-A1 | NON-TOXIC CORROSION-PROTECTION PIGMENTS BASED ON COBALT | STURGILL JEFFREY ALLEN | 2009-06-25 | — | — | US | disclosed |
| WO-2003060192-A1 | NON-TOXIC CORROSION-PROTECTION RINSES AND SEALS BASED ON COBALT | UNIVERSITY OF DAYTON (US) | 2003-07-24 | — | — | WO | disclosed |
| WO-2003060191-A2 | NON-TOXIC CORROSION-PROTECTION CONVERSION COATINGES ABSED ON COBALT | UNIVERSITY OF DAYTON (US) | 2003-07-24 | — | — | WO | disclosed |
| WO-2003060019-A1 | NON-TOXIC CORROSION PROTECTION PIGMENTS BASED ON COBALT | UNIVERSITY OF DAYTON (US) | 2003-07-24 | — | — | WO | disclosed |
| US-6448443-B1 | GENERATED FROM DIVERSIFIABLE SCAFFOLDS SYNTHESIZED FROM THE PYRIDINE-BASED TEMPLATE ISONICOTINAMIDE; ALSO PROVIDES A NOVEL ORTHO-NITROBENZYL PHOTOLINKER; SYNTHESIZED FROM A SHIKIMIC ACID BASED EPOXYOL TEMPLATE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2002-09-10 | — | — | US | disclosed |
| US-6201013-B1 | INOSINE MONOPHOSPHATE DEHYDROGENASE (IMPDH) INHIBITOR; SIDE EFFECT REDUCTION, NON-DRUG RESISTANT | AMERICAN HOME PRODUCTS CORPORATION | 2001-03-13 | — | — | US | disclosed |
| EP-0595995-A4 | ARYLAMIDOALKYL-N-HYDROXYUREA COMPOUNDS HAVING LIPOXYGENASE INHIBITORY ACTIVITY | ABBOTT LAB (US) | 1994-08-24 | — | — | EP | disclosed |
| EP-0595995-A1 | ARYLAMIDOALKYL-N-HYDROXYUREA COMPOUNDS HAVING LIPOXYGENASE INHIBITORY ACTIVITY. | ABBOTT LAB (US) | 1994-05-11 | — | — | EP | disclosed |
| WO-1993002037-A1 | ARYLAMIDOALKYL-N-HYDROXYUREA COMPOUNDS HAVING LIPOXYGENASE INHIBITORY ACTIVITY | ABBOTT LABORATORIES (US) | 1993-02-04 | — | — | WO | disclosed |
| US-5153210-A | Hypoglycemic agent, animal growth regulator; veterinary medicine | BEECHAM GROUP P.L.C. (GB) | 1992-10-06 | — | — | US | disclosed |
| EP-0236624-A2 | Substituted phenyl ethanol amines, processes for their preparation and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1987-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144321-A1 | SYNTHETIC INTERMEDIATES AND PROCESSES | G6PD, GALE, UGGT1 | CASP6 2912/4885TSHR 1519/4885TDP1 1487/4885 |
| US-20250386828-A1 | PLANT GROWTH PROMOTER | MYB, GHITM, PGLS | CASP6 2133/4885TSHR 2129/4885TDP1 3007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.